Ozempic gets green light for diabetes in India, Mystery illness kills 14 kids in Nagpur, Chhindwara

In this segment of 5 Live, the focus is on the Indian drug regulator CDSCO's approval of the blockbuster drug Ozempic. It is cleared for treating type 2 diabetes and reducing risks of serious heart and kidney problems, but explicitly not for weight loss. The programme details how Ozempic, containing the molecule semaglutide, differs from similar drugs like Wegovy and Mounjaro. Dr. Rajesh Rajput explains the physician's role, stating, "It is duty of the doctor actually to find out who is the right patient for which molecule and even within the same molecule which name or which brand." The show also covers the mysterious deaths of 14 children in Nagpur and Chhindwara in 30 days. The cause is being investigated as a possible Acute Encephalitis Syndrome (AES), with teams from the National Institute of Virology and National Center for Disease Control probing the outbreak.